source
- Case Introduction and ctDNA as Emerging Risk Factoronclive · 2mo ago↗ source
- ASCO 2026: All Eyes Are on Daraxonrasib and a Wave of Novel Targeted Therapies in GI MalignanciesAhead of the 2026 ASCO Annual Meeting, experts in GI malignancies share the most anticipated research being presented during the meeting.onclive · 2mo ago↗ source
- MET Alterations in NSCLC: Amplification, Mutations, and Therapeutic StrategiesDecode MET-altered lung cancer: amplification, exon 14 skipping and co-mutations, plus evolving targeted therapies and tumor board insights.onclive · 2mo ago↗ source